Physician profile
Thiru Arasu
NPI 1699770578
$6,179.31
in general payments reported to CMS, 2019-2025
28 companies · $804 in 2025
The $804 reported for 2025 was more than what 80% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $957 · 2020: $314 · 2021: $778 · 2022: $618 · 2023: $1,387 · 2024: $1,322 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,512.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,918.14 | 2019-2025 | Linzess |
| Qol Medical, LLC | $712.52 | 2019-2024 | Sucraid, Sucraid |
| Genzyme Corporation | $642.50 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $595.47 | 2022-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $355.68 | 2020-2023 | |
| Janssen Biotech, INC. | $238.52 | 2023-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $215.15 | 2019-2023 | Epclusa |
| Neuraxis, INC. | $153.94 | 2024 | |
| Celltrion USA INC. | $124.99 | 2025 | Zymfentra |
| Phathom Pharmaceuticals, INC. | $120.17 | 2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $115.97 | 2021 | |
| Ironwood Pharmaceuticals, INC | $104.04 | 2023-2024 | Linzess |
| Rhythm Pharmaceuticals, INC. | $100.26 | 2022-2023 | Imcivree |
| Intra-Sana Laboratories | $88.01 | 2021-2022 | |
| Vivus LLC | $82.08 | 2022-2024 | Pancreaze |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $78.93 | 2021-2024 | Gattex, Eohilia |
| Alcresta Therapeutics, INC. | $74.57 | 2024 | Relizorb |
| Mirum Pharmaceuticals, INC. | $73.69 | 2023-2024 | Livmarli |
| Phadia US INC. | $68.18 | 2019-2025 | Immunocap |
| Travere Therapeutics, INC. | $60.08 | 2019-2021 | |
| Coloplast Corp | $57.52 | 2019-2023 | Peristeen |
| Ipsen Biopharmaceuticals, INC | $52.33 | 2023-2024 | Bylvay |
| Pharming Healthcare, INC. | $50.47 | 2024 | Ruconest |
| Aimmune Therapeutics, INC. | $26.27 | 2024 | |
| Romark Laboratories, Lc | $19.56 | 2019 | |
| Redhill Biopharma INC. | $19.35 | 2020 | |
| Dentsply Ih Ab | $17.21 | 2024 | Navina Rectal Catheter Set Regular |
| Allergan, INC. | $13.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thiru Arasu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.